ModifiedBlue Cross Blue Shield - IllinoisPolicy CPCPLABO11

Biomarker Testing for Autoimmune Rheumatic Disease

This document governs reimbursement criteria for laboratory biomarker testing related to autoimmune rheumatic diseases (e.g., ANA, ENA, RF, anti-CCP, dsDNA) for Blue Cross and Blue Shield of Illinois members and applies to providers submitting claims for these tests.

Policy Summary

PayerBlue Cross Blue Shield - Illinois

PolicyBiomarker Testing for Autoimmune Rheumatic Disease

Policy CodePolicy CPCPLABO11

Change TypeNew policy

Effective DateJan 1, 2026

Next Review Date

Key ActionProviders must submit accurate documentation and claims using valid code combinations; BCBSIL may request additional documentation and applies discretion in policy interpretation.

SourceLink

POLICY UPDATE CHANGES

01/01/2026: New policy

onceANA screening reimbursable during initial workup

up to 2additional ANA/related tests reimbursable per lifetime if new or worse symptoms

up to 4/yrdsDNA testing reimbursable after diagnosis

4 codesproprietary/molecular codes listed

multiple

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Autoimmune Rheumatic Disease Biomarker Testing

Autoimmune rheumatic disease biomarker coverage

Reimbursement positions for antibody and biomarker testing

ALL of the following

ANA screening
- Antinuclear antibody (ANA) screening is reimbursable for individuals with signs or symptoms of an autoimmune disease; reimbursable once during the initial workup.
- Up to two additional ANA tests per lifetime are reimbursable if new or more severe signs or symptoms of an autoimmune disease develop.
ENA panel testing
- Extractable nuclear antigens (ENA) panel testing of specific autoantibodies may be reimbursable when an ANA is abnormal/raised and there is clinical correlation with the appropriate autoimmune disorder.
RF and anti-CCP
- For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti‑cyclic citrullinated peptide (anti‑CCP) antibodies may be reimbursable.
- If initial RF/anti‑CCP testing did not result in a diagnosis of RA, up to two additional tests per lifetime are reimbursable if symptoms persist or additional RA symptoms develop; testing is also reimbursable once during the initial workup.
dsDNA testing
- For individuals with an initial positive ANA and a diagnosis of a systemic autoimmune rheumatic disease, testing for double‑stranded DNA (dsDNA) may be reimbursable up to four times per year.
Condition‑specific antibody testing
- For individuals with a negative or low‑positive ANA, select condition‑specific antibody testing may be reimbursable (examples: anti‑SSA in settings of lupus or Sjogren's syndrome; anti‑Jo‑1 in a unique clinical subset of myositis).

ALL of the following

ANA and/or ENA testing for individuals without symptoms suggestive of an autoimmune disorder (including during wellness visits or general exams without abnormal findings) is not reimbursable.
Testing of specific antibodies in the absence of a positive ANA test is not reimbursable except where specifically noted above.
Monitoring disease activity using ANA testing or ANA titers is not reimbursable.
Proprietary serum biomarker panels, multi‑biomarker panels, or index/algorithm scores for diagnosis, prognosis, or monitoring of RA, SLE, or connective tissue disease are not reimbursable (examples: Vectra DA, PrismRA, AVISE Lupus, AVISE CTD, AVISE SLE Monitor, AVISE SLE prognostic, Seronegative RA profiles, cell‑bound complement activation products).

Operational note: Reimbursable exceptions and frequencies above reflect policy positions; providers should document clinical signs/symptoms, initial test results, and clinical correlation when submitting claims.

Coding — Procedure Codes, Frequencies, and References

Listed proprietary/molecular procedure codesCPT

0312U
0446U
0447U
0521U

Referenced classification and guideline sourcesmixed

No codes listed

inv-04: dsDNA testing frequency

Policy frequency limitdsDNA testing reimbursable up to four times per year for individuals with an initial positive ANA and a diagnosis of systemic autoimmune rheumatic disease.

ApplicabilityApplies after diagnosis of a systemic autoimmune rheumatic disease and following an initial positive ANA test.

Purpose of testingUsed for evaluation/management of individuals with diagnosed systemic autoimmune rheumatic disease as specified in the policy.

Provider Actions — Documentation, Billing, and Review

Documentation Required

Documentation and Discretion

Providers are responsible for submission of accurate documentation of services performed. Submit claims using valid HIPAA-approved code sets and code combinations. Claims should be coded per industry-standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association CPT (and CPT Assistant), Healthcare Common Procedure Coding System (HCPCS), ICD-10-CM/PCS, National Drug Codes, DRG guidelines, CMS National Correct Coding Initiative Policy Manual and CCI table edits, and other CMS guidance. Drug submissions and other claims are subject to review against benefit coverage terms, provider contract language, medical policies, clinical payment and coding policies, and coding software logic. Upon request, BCBSIL may require additional documentation to substantiate services billed. BCBSIL may use reasonable discretion in interpreting and applying this policy to services delivered in a particular case and has full and final discretionary authority for interpretation and application as provided under applicable plan documents.

Use accurate, complete documentation and submit requested records promptly.
Code claims according to industry-standard guidance and HIPAA-approved code sets.
BCBSIL may request additional documentation and applies discretion when reviewing claims.

Note

Definitions — Test Types and Screening

inv-07: Extractable nuclear antigens (ENA) panel testing

Coverage conditionENA panel testing may be reimbursable when ANA is abnormal/raised and there is clinical correlation with the appropriate autoimmune disorder.

Required contextReimbursement requires an abnormal ANA titer plus clinical signs/symptoms consistent with a specific autoimmune disease.

Not reimbursableENA testing is not reimbursable for individuals without symptoms suggestive of an autoimmune disorder or during routine wellness exams.

inv-08: Antinuclear antibody (ANA) testing

Initial workupAntinuclear antibody (ANA) screening reimbursable once during the initial workup for individuals with signs or symptoms of an autoimmune disease.

Additional testing allowance

Revision History and Policy Updates

2026-01-01policy_addedLatest

New policy effective January 1, 2026 (document CPCPLABO11 created).

2025-09-05update_recorded

Policy update history recorded noting the new policy effective 01/01/2026.